Children with asthma and other respiratory diseases often struggle with infections and inflammation. A recent narrative review explores how the respiratory microbiome, including its composition and metabolites, might play a role in these conditions. The study focuses on children as the population of interest. It looks at colonization and dysbiosis within the airway. No specific medications were tested in this review. The authors did not report safety signals or adverse events because this was a review of existing ideas rather than a clinical trial. The review provides new ideas and directions for research on pathogenesis and clinical precision treatment. Because this is a narrative review, it summarizes concepts rather than testing a specific hypothesis with a large group of patients. The evidence here is about potential pathways and future research needs. It does not confirm a cure or a specific treatment yet. This work helps scientists think about how to target the microbiome for better care.
New ideas for treating children with asthma and respiratory infections
Photo by Europeana / Unsplash
What this means for you:
This review offers new ideas for precision treatment of children with respiratory diseases. More on Asthma
Host factors influence viral entry and replication in HPIV infected infants, elderly, and immunocompromised individuals Host factors influence how the parainfluenza virus infects vulnerable people
Frontiers · May 29, 2026
Genetic variants and environmental factors like PM2.5 exposure may increase asthma risk in susceptible individuals Asthma risk tied to genes and air pollution
Frontiers · May 29, 2026
Review of animal models for allergic fungal airway disease and asthma Animal models reveal how fungi trigger severe asthma
Frontiers · May 28, 2026
Systematic review finds vitamin D supplementation offers no lung function benefit for children with asthma Vitamin D supplements don't improve lung function in kids with asthma
Frontiers · May 25, 2026